Australia markets open in 1 hour 12 minutes

CSL Limited (CSL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
292.85-2.25 (-0.76%)
At close: 04:10PM AEST

CSL Limited

45 Poplar Road
Parkville, VIC 3052
61 3 9389 1911

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 25,000

Key executives

NameTitlePayExercisedYear born
Mr. Paul R. Perreault B.A.MD, CEO & Exec. Director3.62MN/A1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFIChief Financial Officer785.02kN/A1965
Dr. Paul F. McKenzie Ph.D.Chief Operating Officer2.11MN/A1966
Dr. Robert Andrew Cuthbertson A.O., AO, BMedSci, FAHMS, FTSE, MBBS, Ph.D.Sr. Adviser & Exec. Director1.05MN/A1955
Mr. Mark DehringHead of Investor RelationsN/AN/AN/A
Mr. Gregory Boss B.S., BS(Hons), J.D.Exec. VP of Legal & Group Gen. CounselN/AN/A1961
Christina HickieSr. Mang. of CommunicationsN/AN/AN/A
Ms. Elizabeth Walker B.A., M.S.Exec. VP & Chief HR OfficerN/AN/A1970
Dr. Karen EtchbergerExec. VP of Quality & Bus. ServicesN/AN/A1958
Dr. Wilfried FreudenbergDepartment Head of Albumin & Immunoglobulins ProductionN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Corporate governance

CSL Limited’s ISS governance QualityScore as of 31 July 2022 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.